Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion

Figures & data

Table 1 Baseline patient characteristics in the two treatment groups

Characteristic	Three IVB group (n=27)	Single IVB group (n=25)
No patients	27	25
Female/male (eyes)	12/15	16/9
Age (years, mean ± SD)	68.0±10.7	69.32±7.8
BCVA (logMAR, mean ± SD)	0.55±0.24	0.56±0.22
CFT (μm, mean ± SD)	514± 172	598±186

Abbreviations: IVB, intravitreal bevacizumab; BCVA, best-corrected visual acuity; CFT, central foveal thickness; logMAR, logarithm of the minimum angle of resolution; SD, standard deviation.

Figure 1 The change in the mean logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR BCVA) from baseline to month 12.

Notes: In the one-injection group (solid circles), the mean logMAR BCVA improved slightly from 0.56 at baseline to 0.47 at month 1 (P=0.04) and improved significantly to 0.33 at month 12 (P<0.001). in the three-injection group (open circles), the mean logMAR BCVA improved further to 0.40 at month 1 (P<0.001) and improved significantly from 0.55 at baseline to 0.26 at month 12 (P<0.001). There was no significant between-group difference in the mean logMAR BCVA at month 12 (P=0.389).

Figure 2 The mean change in central foveal thickness (CFT) from baseline to month 12.

Notes: The mean CFT decreased significantly from 598±186 μm at baseline to 348±134 μm at month 12 in the one-injection group (solid circles; P<0.001) and from 514±172 μm at baseline to 293±102 μm at month 12 in the three-injection group (open circles; P<0.001). There was no significant between-group difference in the mean CFT at month 12 (P=0.101).

Table 2 Comparison of results of intravitreal injection of bevacizumab at 12 months between previous studies and the current study

Study	Current study single injection	Jaissle et al^Citation12	Kondo et al^Citation13	Current study three monthly injections	Demir et al^Citation15
Eyes	25	23	50	27	33
Injections	Single	Single	Single	Three monthly	Three monthly
Baseline BCVA	0.56	0.50	0.53	0.55	0.66
BCVA at 12 months	0.33	0.20	0.26	0.26	0.22
Baseline CFT	598	395	523	514	494
CFT at 12 months	348	255	305	293	262
Additional injections	1.1	2.4	1.0	1.3	2.3

Abbreviations: BCVA, best-corrected visual acuity; CFT, central foveal thickness.

JaissleGBLeitritzMGeliskenFZiemssenFBartz-SchmidtKUSzurmanPOne-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusionGraefes Arch Clin Exp Ophthalmol20092471273318696094

 PubMed Web of Science ®Google Scholar

KondoMKondoNItoYIntravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: Results after 12 months and multiple regression analysisRetina20092991242124819672216

 PubMed Web of Science ®Google Scholar

DemirMObaEGulkilikGOdabasiMOzdalEIntravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month resultsClin Ophthalmol2011574574921750607

 PubMedGoogle Scholar